Cindy Gingrich-Baker

Title: The Innovations of Cindy Gingrich-Baker

Introduction

Cindy Gingrich-Baker is a notable inventor based in Boylston, MA (US). She has made significant contributions to the field of biopharmaceuticals, particularly in the study and treatment of granulocytic Ehrlichia. With a total of 2 patents, her work has advanced the understanding of this important area in medical research.

Latest Patents

Cindy's latest patents focus on cell lines infected with granulocytic Ehrlichia, vaccines, diagnostics, and methods related to this pathogen. The first patent describes a human promyelocytic leukemia cell line infected with granulocytic Ehrlichia, along with methods for continually growing the bacteria, developing vaccines, and identifying the pathogen in animals. The second patent expands on this by detailing various cell lines, including acute myelogenous leukemia and histiocytic lymphoma cell lines, that are also infected with granulocytic Ehrlichia. Both patents emphasize the importance of developing effective vaccines and diagnostic methods to prevent ehrlichiosis in animals.

Career Highlights

Cindy is currently employed at Aquila Biopharmaceuticals Inc., where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of granulocytic Ehrlichia and its implications for both human and animal health.

Collaborations

Cindy collaborates with Richard T. Coughlin, contributing to the innovative research at Aquila Biopharmaceuticals Inc. Their combined expertise enhances the potential for breakthroughs in the field.

Conclusion

Cindy Gingrich-Baker's contributions to the field of biopharmaceuticals through her patents and research are noteworthy. Her work on granulocytic Ehrlichia has the potential to impact both veterinary and human medicine significantly.